Gastric cancer is a burden in medicine with a male predominant gender relation. Although the incidence of gastric cancer has
decreased in the last few decades, an increase of females and elderly patients was also reported. The standard of care for gastric
cancer is radical surgical resection with reported morbidity rates between 20 and 46% and a postoperative observed mortality
rate between 0.8 ââ¬â 10% , depending on the expertise, and in case of locally advanced tumor category ,from multimodal therapy. The
Cochrane review from 2010 investigated 5,726 patients and revealed that chemotherapy significantly improves survival in advanced gastric
cancer patients compared to best supportive care. The type of the surgical resection depends on the tumor location, size, cancer depth,
clinical staging and the histological subtype as well as a lymphovascular invasion and contents of a radical subtotal or a total gastrectomy with
D-I and/or D-II lymphadenectomy. D-I lymphadenectomy contains the perigastric lymph nodes, while a D-II lymphadenectomy contains
the D-I-lymphadenectomy plus the resection of the lymph nodes along the hepatic, left gastric, celiac and splenic arteries as well as those in
the splenic hilus. In western countries, the diagnosis of gastric cancer is mostly in advanced cancer tumor categories in contrast with
eastern countries where most of the cases are of early cancer (about 50%).
Last date updated on September, 2024